Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, Sangro, Bruno · 2022 · The Lancet Oncology

Abstract

BACKGROUND Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1-2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients with advanced hepatocellular carcinoma. METHODS In this randomised, open-label, phase 3 trial done at medical centres across 22 countries and territories in Asia, Australasia, Europe, and North America, patients at least 18 years old with histologically confirmed advanced hepatocellular carcinoma not eligible for, or whose disease had progressed after, surgery or locoregional treatment; with no previous systemic therapy for hepatocellular carcinoma, with Child-Pugh class A and Eastern Cooperative Oncology Group performance status score of 0 or 1, and regardless of viral hepatitis status were randomly assigned (1:1) via an interactive voice response system to receive nivolumab (240 mg intravenously every 2 weeks) or sorafenib (400 mg orally twice daily) until disease progression or unacceptable toxicity. The primary endpoint was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study drug. This completed trial is registered with ClinicalTrials.gov, NCT02576509. FINDINGS Between Jan 11, 2016, and May 24, 2017, 743 patients were randomly assigned to treatment (nivolumab, n=371; sorafenib, n…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00604-5

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 33 references

Research works printed but not linked: 2

  1. Crocenzi, 2017, Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study, Proc Am Soc Clin Oncol, 35
  2. Finn, 2021, IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC), Proc Am Soc Oncol, 39, 267

Cited by

See all 1,106

Metadata

Authors
Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., Wyrwicz, L., Schott, E., Choo, S. P., Kelley, R. K., Sieghart, W., Assenat, E., Zaucha, R., Furuse, J., Abou-Alfa, G. K., El-Khoueiry, A. B., Melero, I., Begic, D., Chen, G., Neely, J., Wisniewski, T., Tschaika, M., & Sangro, B.
Affiliations
  • University of Hong Kong (HK)
  • National Cancer Center (KR)
  • University of California, Los Angeles (US)
  • National Taiwan University (TW)
  • Centre Hospitalier Universitaire de Lille (FR)
  • Centre Eugène Marquis (FR)
  • Kindai University (JP)
  • Memorial Sloan Kettering Cancer Center (US)
  • Hôpital de la Croix-Rousse (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
  • Helios Klinikum Emil von Behring (DE)
  • National Cancer Centre Singapore (SG)
  • UCSF Helen Diller Family Comprehensive Cancer Center (US)
  • Medical University of Vienna (AT)
  • Gdańsk Medical University (PL)
  • Kyorin University (JP)
  • USC Norris Comprehensive Cancer Center (US)
  • Clinica Universidad de Navarra (ES)
  • Bristol-Myers Squibb (United States) (US)
Corresponding author
Yau, Thomas
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2022-01
Volume
23
Issue
1
Pages
77-90
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4200118825
Cited by
1,106
References
33
Citations by year
2026: 120 · 2025: 230 · 2024: 299 · 2023: 264 · 2022: 193
FWCI
106.17
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Yonsei University
  • Ono Pharmaceutical
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
nivolumab, sorafenib, advanced hepatocellular carcinoma, immune checkpoint inhibitors, first-line therapy, overall survival, immune-related adverse events, treatment safety, anti-PD-1, progression-free survival, treatment discontinuation
MeSH terms
Sorafenib, Nivolumab, Aged, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00604-5
The paper
Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., Wyrwicz, L., Schott, E., Choo, S. P., Kelley, R. K., Sieghart, W., Assenat, E., Zaucha, R., Furuse, J., Abou-Alfa, G. K., . . . Sangro, B. (2022). Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00604-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.